US09609G2093
© BusinessWire
02.06.2025
BLUE
LISTED
NASDAQ
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
News Preview
bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird’s common stock has ceased trading and will no longer...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
BLUE
LISTED
NASDAQ
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
News Preview
Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right pe...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
BLUE
LISTED
NASDAQ
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
16.05.2025
BLUE
LISTED
NASDAQ
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
News Preview
As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
14.05.2025
BLUE
LISTED
NASDAQ
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. Under the terms of the amended agreement bluebird stockholders can...
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
BLUE
LISTED
NASDAQ
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025.
Stockholders that hold shares of bluebird common stock...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
BLUE
LISTED
NASDAQ
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) announced today that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received.
N...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
BLUE
LISTED
NASDAQ
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
BLUE
LISTED
NASDAQ
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone....
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
BLUE
LISTED
NASDAQ
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
BLUE
LISTED
NASDAQ
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
BLUE
LISTED
NASDAQ
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
News Preview
Ademi LLP is investigating bluebird (Nasdaq: BLUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Carlyle and SK Capital.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation t...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
21.02.2025
BLUE
LISTED
NASDAQ
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holde...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
BLUE
LISTED
NASDAQ
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutic...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2024
BLUE
LISTED
NASDAQ
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral p...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2024
BLUE
LISTED
NASDAQ
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Expositi...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces 1-for-20 Reverse Stock Split
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
BLUE
LISTED
NASDAQ
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
BLUE
LISTED
NASDAQ
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress.
“Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial la...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
BLUE
LISTED
NASDAQ
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it partially adjourned its annual meeting of stockholders (“Annual Meeting”) on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive prox...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
BLUE
LISTED
NASDAQ
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular blood transfusions will be presented at the 66th American Society of Hematology (...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2024
BLUE
LISTED
NASDAQ
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement awards of 242,500 restricted stock units (RSUs). This includes the previously disclosed 100,000 RSUs granted to the Company’s CFO, James Sterling, with a grant date of September 30, 2024 and 142,500...
Themefolio
Profiler
Peergroup
© BusinessWire
27.09.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”).
With the completion of this filing, the Company is now current in its SEC periodic reporting obligations.
About bluebird bio, Inc....
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
BLUE
LISTED
NASDAQ
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
News Preview
Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating e...
Themefolio
Profiler
Peergroup
© BusinessWire
13.09.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023. Today, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), includ...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces September Investor Events
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:
2024 Wells Fargo Healthcare Conference, Wednesday, September 4, at 12:45 p.m. ET at the Encore Boston Harbor, Everett, MA
Morgan Stanley 22nd Annual Global Healthcare Confere...
Themefolio
Profiler
Peergroup
© BusinessWire
23.08.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces Receipt of Expected Notices from Nasdaq
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the “notices”) on August 20, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the “Q1 2024 Form 10-Q”) and June 30, 2024 (the “Q2 2024 Form...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2024
BLUE
LISTED
NASDAQ
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported second quarter results and business highlights for the quarter ended June 30, 2024, including recent commercial and operational progress.
“We are seeing clear evidence that our commercial launch is accelerating, with over 20 cell collections completed in sickle ce...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces Second Quarter 2024 Results Call Date
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8:00 a.m. ET.
To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 2776050....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
